Cardiac Rhythm News
Abbott has announced that the US Food and Drug Administration (FDA) has approved the company’s Amplatzer Talisman PFO Occlusion System to treat people with a patent foramen ovale (PFO)—a small opening between the upper chambers of the heart—who are at risk of recurrent ischaemic stroke.
Economic analyses from the WRAP-IT study, sponsored by Medtronic, demonstrate the Tyrx cardiac absorbable antibacterial envelope’s (Tyrx Envelope) cost effectiveness in European markets for patients at increased risk of infections.
Medtronic has received US Food and Drug Administration (FDA) expanded approval for the Arctic Front family of cardiac cryoablation catheters for the treatment of recurrent symptomatic paroxysmal atrial fibrillation (AF) as an alternative to antiarrhythmic drug (AAD) therapy as an initial rhythm control strategy.
iRhythm Technologies has announced two US Food and Drug Administration (FDA) 510K clearances—one for a new and improved design of its flagship monitor and a second for updated artificial intelligence (AI) capabilities.
A significant proportion of cardiology trainees are uncomfortable with using telemedicine and feel that better preparation for new-tech medicine is needed, findings of a survey published in the Canadian Journal of Cardiology indicate.
Abbott has announced a new trial focused on improving the treatment for people simultaneously battling both atrial fibrillation (AF) and heart failure.
Subcutaneous implantable cardioverter-defibrillator (S-ICD) devices have demonstrated a cardioversion efficacy rate of 98% over a period of at least five years in the EFFORTLESS study—the results of which were presented in a late-breaking presentation at the 2021 European Heart Rhythm Association congress.
Cardialen has announced the publication of a first-in-human study in the Journal of the American College of Cardiology: Clinical Electrophysiology investigating its low-voltage MultiPulse therapy to terminate atrial fibrillation (AF).
A study of nearly 108,000 people has found that people who regularly drink a modest amount of alcohol are at increased risk of atrial fibrillation (AF).
The HeartLight System is a catheter ablation technology for controlled and consistent pulmonary vein isolation (PVI), the gold standard treatment for atrial fibrillation (AF). HeartLight is a treatment option for some patients whose AF is insufficiently controlled with medication.
Stay Up-To-Date on jobs and industry news.
Sign up for the CathLab.com newsletter today!